Ligand validation:3KZI

PL9: 2,3-DIMETHYL-5-(3,7,11,15,19,23,27,31,35-NONAMETHYL-2,6,10,14,18,22,26,30,34-HEXATRIACONTANONAENYL-2,5-CYCLOHEXADIENE-1,4-DIONE-2,3-DIMETHYL-5-SOLANESYL-1,4-BENZOQUINONE

PL9 is a Ligand Of Interest in 3KZI designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3KZI_PL9_D_357	1%	3%	0.441	0.65	3.11	2.92	23	26	36	0	100%	1
5WS6_PL9_D_405	97%	37%	0.055	0.967	0.69	1.76	2	21	0	0	100%	1
5B5E_PL9_d_406	96%	33%	0.054	0.965	1.05	1.59	4	12	0	0	100%	1
5GTI_PL9_d_405	96%	36%	0.053	0.962	0.64	1.86	2	22	0	0	100%	1
5V2C_PL9_d_407	96%	34%	0.069	0.978	1.27	1.32	8	10	0	0	100%	1
5B66_PL9_D_412	93%	35%	0.077	0.97	1.06	1.51	3	12	0	0	100%	1
1VF5_PL9_Q_1305	98%	4%	0.062	0.984	3.4	2.39	21	16	32	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.